Codetta Bio™, a leading innovator in multi-omic solutions that integrate ultrasensitive protein quantitation with simultaneous analysis of nucleic acids (RNA and DNA), today announced a significant expansion of its global commercial organization. This strategic move strengthens the company’s ability to meet growing demand for its Concerto™ system as Codetta transitions from its Technology Access Program (TAP) to full commercial launch.

South 8 Technologies, the developer of LiGas®, the world’s first liquefied gas electrolyte for lithium-ion batteries, today announced an $11 million follow-on funding round co-led by the venture arm of W. L. Gore & Associates (Gore) and Lockheed Martin Ventures. The capital will accelerate commercialization of South 8’s LiGas battery cells for aerospace and defense applications that require reliable energy in the harshest environments.

6K Additive, a global leader in advanced metal powders and alloy additions, today announced the successful completion of its IPO on the Australian Stock Exchange (ASX), raising A$48m at an offer price of A$1.00 per CDI (Offer Price). At the Offer Price, 6K Additive has an initial market capitalization of approximately A$267m and an enterprise value of approximately A$206m. The Company’s CDIs will trade on ASX under the ticker symbol 6KA. The IPO attracted strong support from a range of new institutional, family office and sophisticated investors in Australia and overseas, together with existing shareholders. Trusted by leading organizations across aerospace, defense, space, medical, energy, and automotive sectors, 6K Additive plans to use the newly secured capital to support its expansion plan to better serve its growing customer base and broaden its product offerings.

Jonathan Rowntree, Chief Executive Officer of Niron Magnetics, testified Wednesday before the U.S. House Select Committee on the Chinese CCP, presenting the company’s breakthrough Iron Nitride magnet technology as a solution to reducing America’s critical dependence on rare earth materials.

Medcrypt Inc., the leader in medical device cybersecurity, today announced the launch of Medcrypt Security Intelligence, the industry’s first expert-enhanced software solution for assessing, benchmarking, and advancing cybersecurity program maturity across the medical device lifecycle.

ImmunoScape Pte. Ltd., an A*STAR spin out backed by Amgen Ventures and EDBi that is developing next-generation TCR-based cancer immunotherapies, today announced an exclusive in-licensing deal with Cue Biopharma Inc. (Nasdaq: CUE) to lead the development of a distinct new class of therapies to attack solid tumor cancers. The deal provides ImmunoScape with exclusive access to Cue Biopharma’s clinical-stage Immuno-STAT® molecules in oncology.